Case Report: Serial onabotulinumtoxinA injections for ocular bobbing after pontine stroke

Ocular bobbing is a rare eye movement disorder associated with destructive pontine lesions that can cause disabling oscillopsia and visual impairment, with no established treatment. We report a 76-year-old woman who developed ocular bobbing following a pontine infarction involving the left lateral pons with extension across the midline and into the left middle cerebellar peduncle, accompanied by bilateral horizontal gaze palsies, left sixth and seventh cranial nerve palsies, acquired pendular nystagmus, and strabismus. Because of persistent, functionally limiting oscillopsia, she underwent serial onabotulinumtoxinA injections into selected extraocular muscles, primarily targeting the bilateral vertical rectus muscles to reduce the vertical oscillatory component of ocular bobbing, with horizontal rectus injections adjusted as needed for sixth nerve palsy-related strabismus. Eleven injection sessions were performed between October 2022 and October 2025. Following treatment, the patient consistently reported improved visual stability and reduced oscillopsia, with benefit lasting approximately 6–8 weeks after each injection. Three-dimensional video-oculography demonstrated quantitatively smaller vertical oscillation amplitudes after treatment, with the greatest reduction observed 1.5 months after the second injection. Visual acuity remained relatively stable throughout treatment. Injections were performed without documented procedural complications; however, treatment-related changes in ocular alignment and motility occurred, including transient worsening of left hypotropia after the initial right inferior rectus injection. These effects underscore the need to distinguish procedural safety from the expected and potentially clinically significant ocular motor consequences of extraocular muscle chemodenervation. Serial extraocular muscle onabotulinumtoxinA injections were associated with reproducible subjective improvement in oscillopsia and objective reduction of ocular bobbing. This case suggests that extraocular muscle chemodenervation may represent a potential therapeutic approach for disabling ocular bobbing, although further study is needed to establish its efficacy, safety, and optimal treatment strategy.

Authors

Institutions

Publication Details

Journal
Frontiers in Ophthalmology
Published
2026-11-16
DOI
https://doi.org/10.3389/fopht.2026.1993354
Primary Topic
Botulinum Toxin and Related Neurological Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Serial onabotulinumtoxinA injections for ocular bobbing after pontine stroke

Yaping Joyce Liao, Ann Shue, Rishita Rama Pujari, Justin Wei Siong Lam et al.
Frontiers in Ophthalmology
Botulinum Toxin and Related Neurological Disorders
article

Case Report: Serial onabotulinumtoxinA injections for ocular bobbing after pontine stroke

Yaping Joyce Liao, Ann Shue, Rishita Rama Pujari, Justin Wei Siong Lam, EunA Koo, Joyce Wan-Jou Kuo
article en

Abstract

Ocular bobbing is a rare eye movement disorder associated with destructive pontine lesions that can cause disabling oscillopsia and visual impairment, with no established treatment. We report a 76-year-old woman who developed ocular bobbing following a pontine infarction involving the left lateral pons with extension across the midline and into the left middle cerebellar peduncle, accompanied by bilateral horizontal gaze palsies, left sixth and seventh cranial nerve palsies, acquired pendular nystagmus, and strabismus. Because of persistent, functionally limiting oscillopsia, she underwent serial onabotulinumtoxinA injections into selected extraocular muscles, primarily targeting the bilateral vertical rectus muscles to reduce the vertical oscillatory component of ocular bobbing, with horizontal rectus injections adjusted as needed for sixth nerve palsy-related strabismus. Eleven injection sessions were performed between October 2022 and October 2025. Following treatment, the patient consistently reported improved visual stability and reduced oscillopsia, with benefit lasting approximately 6–8 weeks after each injection. Three-dimensional video-oculography demonstrated quantitatively smaller vertical oscillation amplitudes after treatment, with the greatest reduction observed 1.5 months after the second injection. Visual acuity remained relatively stable throughout treatment. Injections were performed without documented procedural complications; however, treatment-related changes in ocular alignment and motility occurred, including transient worsening of left hypotropia after the initial right inferior rectus injection. These effects underscore the need to distinguish procedural safety from the expected and potentially clinically significant ocular motor consequences of extraocular muscle chemodenervation. Serial extraocular muscle onabotulinumtoxinA injections were associated with reproducible subjective improvement in oscillopsia and objective reduction of ocular bobbing. This case suggests that extraocular muscle chemodenervation may represent a potential therapeutic approach for disabling ocular bobbing, although further study is needed to establish its efficacy, safety, and optimal treatment strategy.

Frontiers in OphthalmologyVol. 6
Neurosciences Institute (US), Stanford Medicine (US), Case Western Reserve University (US), Stanford University (US)
Good health and well-being
Botulinum Toxin and Related Neurological Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon